ATE405656T1 - Herstellungsverfahren für rekombinante proteine, plasmide und modifizierte zellen - Google Patents

Herstellungsverfahren für rekombinante proteine, plasmide und modifizierte zellen

Info

Publication number
ATE405656T1
ATE405656T1 AT95931242T AT95931242T ATE405656T1 AT E405656 T1 ATE405656 T1 AT E405656T1 AT 95931242 T AT95931242 T AT 95931242T AT 95931242 T AT95931242 T AT 95931242T AT E405656 T1 ATE405656 T1 AT E405656T1
Authority
AT
Austria
Prior art keywords
plasmids
pct
production process
recombinant proteins
modified cells
Prior art date
Application number
AT95931242T
Other languages
English (en)
Inventor
Beatrice Cameron
Joel Crouzet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE405656T1 publication Critical patent/ATE405656T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT95931242T 1994-09-16 1995-09-14 Herstellungsverfahren für rekombinante proteine, plasmide und modifizierte zellen ATE405656T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9411049A FR2724665B1 (fr) 1994-09-16 1994-09-16 Procede de production de proteines recombinantes, plasmides et cellules modifiees

Publications (1)

Publication Number Publication Date
ATE405656T1 true ATE405656T1 (de) 2008-09-15

Family

ID=9466987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95931242T ATE405656T1 (de) 1994-09-16 1995-09-14 Herstellungsverfahren für rekombinante proteine, plasmide und modifizierte zellen

Country Status (19)

Country Link
US (1) US6143518A (de)
EP (1) EP0781341B1 (de)
JP (1) JP3696247B2 (de)
KR (1) KR100391752B1 (de)
AT (1) ATE405656T1 (de)
AU (1) AU708080B2 (de)
CA (1) CA2197804C (de)
DE (1) DE69535815D1 (de)
DK (1) DK0781341T3 (de)
ES (1) ES2313721T3 (de)
FI (1) FI120238B (de)
FR (1) FR2724665B1 (de)
IL (1) IL115308A (de)
MX (1) MX9701614A (de)
NO (1) NO320374B1 (de)
PT (1) PT781341E (de)
TW (1) TW517086B (de)
WO (1) WO1996008572A1 (de)
ZA (1) ZA957750B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618001D0 (en) 1996-08-29 1996-10-09 Nyfotek As Novel expression vectors
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
EP0998945A1 (de) * 1998-09-30 2000-05-10 Transgene S.A. Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie
DE69929638T2 (de) 1999-01-20 2006-09-21 Bayer Healthcare Ag Plasmide, deren Konstruktion und Anwendung zur Herstellung von Interleukin-4 und dessen Muteine
EP1022337B1 (de) * 1999-01-20 2006-07-26 Bayer HealthCare AG Plasmide, deren Konstruktion und deren Verwendung zur Herstellung von Interleukin-4 und Interleukin-4 Muteine
CA2388003C (en) * 1999-10-19 2013-02-19 Bharat Biotech International, Ltd. Expression of recombinant mature lysostaphin
US9051589B2 (en) * 2005-10-27 2015-06-09 Kaneka Corporation Plasmid vector and transformant stably retaining plasmid
JP5650368B2 (ja) * 2005-10-27 2015-01-07 株式会社カネカ 新規プラスミドベクター及びプラスミドを安定に保持する形質転換体
NZ588895A (en) 2008-05-13 2012-07-27 Clarassance Inc Recombinant human CC10 (rhCC10 aka uteroglobin) and compositions thereof for use in the treatment of nasal rhinitis
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
JP5944316B2 (ja) 2009-10-15 2016-07-05 セラブロン セラピューティクス，インコーポレイテッド インフルエンザ処置用の組換え型ヒトｃｃ１０タンパク質
BR102014014502B1 (pt) * 2014-06-13 2020-09-15 Ouro Fino Saúde Animal Ltda Vetor de expressão

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK410783D0 (da) * 1982-09-16 1983-09-09 Benzon A Salfred Fremgangsmade til stabilisering af plasmider
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
NZ220917A (en) * 1986-07-11 1991-05-28 Merck & Co Inc Human and bovine acidic fibroblast growth factor vectors, hosts and compositions
US5175147A (en) * 1988-08-19 1992-12-29 Takeda Chemical Industries, Ltd Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
FR2642086B1 (fr) * 1989-01-26 1992-09-04 Sanofi Sa Gene recombinant codant pour un facteur basique de croissance des fibroblastes et ledit facteur
EP0406738A3 (en) * 1989-07-03 1991-08-14 Takeda Chemical Industries, Ltd. Production of acidic fgf protein
FR2661188B1 (fr) * 1990-04-24 1994-07-22 Rhone Poulenc Sante Nouveaux vecteurs de clonage et/ou d'expression, procede de preparation et leur utilisation.

Also Published As

Publication number Publication date
KR100391752B1 (ko) 2003-10-22
DK0781341T3 (da) 2009-01-05
WO1996008572A1 (fr) 1996-03-21
MX9701614A (es) 1997-06-28
TW517086B (en) 2003-01-11
EP0781341B1 (de) 2008-08-20
IL115308A (en) 2009-07-20
NO320374B1 (no) 2005-11-28
FR2724665A1 (fr) 1996-03-22
EP0781341A1 (de) 1997-07-02
DE69535815D1 (de) 2008-10-02
AU3475495A (en) 1996-03-29
CA2197804A1 (fr) 1996-03-21
ZA957750B (en) 1996-04-24
US6143518A (en) 2000-11-07
AU708080B2 (en) 1999-07-29
JPH10505746A (ja) 1998-06-09
CA2197804C (fr) 2010-11-16
PT781341E (pt) 2008-11-20
NO971139L (no) 1997-03-12
FR2724665B1 (fr) 1996-12-20
FI971100L (fi) 1997-03-14
NO971139D0 (no) 1997-03-12
IL115308A0 (en) 1995-12-31
JP3696247B2 (ja) 2005-09-14
ES2313721T3 (es) 2009-03-01
FI971100A0 (fi) 1997-03-14
FI120238B (fi) 2009-08-14

Similar Documents

Publication Publication Date Title
ATE405656T1 (de) Herstellungsverfahren für rekombinante proteine, plasmide und modifizierte zellen
NO950534D0 (no) Modufiserte soppceller og fremgangsmåter for fremstilling av rekombinante produkter
DE69834267D1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
IL173399A (en) Circular dna molecules, processes for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medical products for producing recombinant proteins in vivo
ATE85081T1 (de) Analoge des gewebespezifischen plasminogenaktivators.
IL101024A0 (en) Process for the activation of recombinant proteins
BR9811592A (pt) Oxidase de citocinina
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
DE3856240D1 (de) Herstellung der p1 proteine und impfstoffe gegen gonorrhöe
DE69638365D1 (de) Neue cytokinine aus vögeln und dafür codierende genetische sequenzen
FI942442A0 (fi) Proteiinien tuotto 7B2-proteiinia käyttäen
ATE255638T1 (de) Nukleotidsequenzen und gegen cycloheximid resistente proteine
DE69022901D1 (de) Streptokinase-Proteine, entsprechende Gene, entsprechende Plasmide und Verfahren zu deren Herstellung.
CO4480058A1 (es) Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE68920651D1 (de) Hühner-beta-Actin-Promoter und menschliches Faktor VIII-C-Gen enthaltende Plasmide, Transformanten und Verfahren zur Herstellung des menschlichen Faktors VIII-C.
DE59410428D1 (de) Cholesterinoxidase aus brevibacterium sterolicum
ATE310093T1 (de) Promotor vom gen des k.lactis rp28 ribosomalen proteins und anwendung davon
FI954889A7 (fi) Proteiini, jolla on TPO-aktiviteetti
EP0292803A3 (de) Verfahren zur Herstellung eines HMG-CoA-Reduktase-ähnlichen Proteins
DE69032453D1 (de) Expressionsvektoren und verfahren zur herstellung intrazellularer proteine
RO116403B1 (ro) Derivaţi ai teofilinei şi teobrominei şi procedeu de preparare
MX9504057A (es) Proteina que tiene actividad tpo.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0781341

Country of ref document: EP